|
|
Dave
P. Miller is Director of Statistical Analysis for ICON Clinical Research’s Lifecycle
Sciences Group (formerly Ovation Research
Group)
Publications
Nallamothu
BK, Blaney ME, Morris SM, Parsons L, Miller DP, Canto JG, Barron HV,
Krumholz HM. Acute Reperfusion Therapy in Myocardial Infarction from
1994-2003. Am J Med.
2007 Aug ;120 (8):693-699.
Chen
H, Gould MK, Blanc PD, Miller DP, Kamath TV, Lee JH, Sullivan SD;
for the TENOR Study Group. Asthma control, severity, and quality of life:
quantifying the effect of uncontrolled disease. J Allergy Clin Immunol.
2007 Aug;120(2):396-402.
Padman
R, McColley SA, Miller DP, Konstan MW, Morgan WJ, Schechter MS, Ren
CL, Wagener JS; Investigators and Coordinators of the Epidemiologic Study
of Cystic Fibrosis. Padman R, McColley SA, Miller DP, Konstan MW, Morgan
WJ, Schechter MS, Ren CL, Wagener JS; Investigators and Coordinators of the
Epidemiologic Study of Cystic Fibrosis. Pediatrics. 2007 Mar;119(3)
Miller
MK, Lee JH, Miller DP, Wenzel SE; TENOR Study Group. Recent asthma
exacerbations: a key predictor of future exacerbations. Respir Med.
2007 Mar;101(3):481-9.
Haselkorn
T, Borish L, Miller DP, Weiss ST, Wong DA. High prevalence of skin test positivity in severe or
difficult-to-treat asthma. J Asthma. 2006 Dec;43(10):745-52.
Zuley
ML, Willison KM, Bonaccio E, Miller DP, Leong DL, Seifert PJ,
Somerville P, Destounis S. Full-field
digital mammography on LCD versus CRT monitors. Am J Roentgenol. 2006 Dec;187(6):1492-8.
Pinto
DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates
ER, Frederick PD, Miller DP, Carrozza JP Jr, Antman EM, Cannon CP,
Gibson Hospital delays in reperfusion for ST-elevation myocardial
infarction: implications when selecting a reperfusion strategy. Circulation.
2006 Nov 7;114(19):2019-25.
Raffy
P, Gaudeau Y, Miller DP, Moureaux JM, Castellino RA. Computer-aided detection of solid
lung nodules in lossy compressed multidetector computed tomography chest
exams. Acad Radiol. 2006 Oct;13(10):1194-203.
Lee
JH, Haselkorn T, Chipps B, Miller DP, Wenzel S. Gender differences
in IgE-mediated allergic asthma in the epidemiology and natural history of
asthma: outcomes and treatment regimens (TENOR) study. J Asthma 2006
Apr;43(3):179-84.
Miller
MK, Johnson C, Miller DP, Deniz Y, Bleecker ER, Wenzel S. Severity
assessment in asthma: An evolving concept. J Allergy Clin Immunol. 2005;
116: 990-5.
Mascia
K, Haselkorn T, Deniz Y, Miller DP, Bleecker ER, Borish L. Aspirin
sensitivity and severity of asthma: Evidence for irreversible airway
obstruction in patients with severe or difficult-to-treat asthma. J
Allergy Clin Immunol. 2005; 970-5.
Miller
DP.
Emphasis on CIs when p-values are not appropriate. Radiology. 2002 Sep ;224 (3):932-3
Zitter
JN, Mazonson PD, Miller DP, Hulley SB, Balmes JR. “Aircraft cabin
air recirculation and symptoms of the common cold.” JAMA 2002 Jul
24-31;288(4):483-6.
Henke
CJ, Villa KF, Aichelmann-Reidy ME, Armitage GC, Eber RM, Genco RJ, Killoy
WJ, Miller DP, Page RC, Polson AM, Ryder MI, Silva SJ, Somerman MJ,
Van Dyke TE, Wolff LF, Evans CJ, Finkelman RD. “An economic evaluation of a chlorhexidine chip for
treating chronic periodontitis: the CHIP (chlorhexidine in periodontitis)
study.” J Am Dent Assoc. 2001 Nov;132(11):1557-69.
Mathias
SD, Colwell HH, Miller DP, Pasta DJ, Henning JM, Ofman JJ.
“Health-Related quality-of-life and quality-days incrementally gained in
symptomatic nonerosive GERD patients treated with lansoprazole or
ranitidine.” Dig Dis Sci. 2001 Nov;46(11):2416-23.
Miller
DP, Villa KF, Hogue SL, Sivapathasundaram D.
“Birth and first-year costs for mothers and infants attributable to
maternal smoking.” Nicotine and
Tobacco Research 2001, 3:25-35.
Anderson
KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, Miller DP,
Ferguson JJ 3rd, Willerson JT, Weisman HF, Topol EJ. “Long-term mortality
benefit with abciximab in patients undergoing percutaneous coronary
intervention.” J Am Coll Cardiol. 2001 Jun 15;37(8):2059-65.
Pilote
L, Miller DP, Califf RM, Topol EJ. Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded Coronary
Arteries (GUSTO-I) Investigators. “Recurrent ischemia after thrombolysis
for acute myocardial infarction.” Am Heart J. 2001
Apr;141(4):559-65.
Grossfeld
GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, Carroll PR.
“Does the completeness of prostate sampling predict outcome for patients
undergoing radical prostatectomy?: data from the CAPSURE database.” Urology.
2000 Sep 1;56(3):430-5.
Brieger
DB, Mak KH, Miller DP, Califf RM, Topol EJ. “Hierarchy of risk based on history
and location of prior myocardial infarction in the thrombolytic era.”
GUSTO-I Investigators. Am Heart J. 2000 Jul;140(1):29-33.
Grossfeld
GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, Henning JM,
Stier DM, Carroll PR. “Impact
of positive surgical margins on prostate cancer recurrence and the use of
secondary cancer treatment: data from the CaPSURE database.” J Urol.
2000 Apr;163(4):1171-7.
Miller
DP, Pasta DJ, Mathias SD, Colwell HH, Henning JM.
“Quality-days incrementally gained: a new approach for short-term
evaluations based on the extended Q-TWiST method illustrated in a clinical
study of reflux disease patients.” Drug
Information Journal 2000, 34:469-481.
Mathias
SD, Colwell HH, Miller DP,
Moreland LW, Buatti M, Wanke L. “Health-related quality of life and
functional status of patients with rheumatoid arthritis randomly assigned
to receive etanercept or placebo.” Clin
Ther, 22(1):128-39,
January 2000.
Narins
CR, Miller DP, Califf RM, Topol EJ. “The relationship between
periprocedural myocardial infarction and subsequent target vessel
revascularization following percutaneous coronary revascularization:
insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor
antagonist 7E3 in Preventing Ischemic Complications.” J Am Coll Cardiol, 33(3):647-53, March 1999.
Kong
DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA,
Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. “Clinical outcomes of
therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin
in ischemic heart disease.” Circulation,
98(25):2829-35, December 22-29 1998.
Asher
CR, Miller DP, Grimm RA, Cosgrove DM 3rd, Chung MK.
“Analysis of risk factors for development of atrial fibrillation early
after cardiac valvular surgery.” Am J
Cardiol, 82(7):892-5, October 1998.
Ghaffari
S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller
DP, Califf RA, Topol EJ. "Platelet glycoprotein IIb/IIIa receptor
blockade with abciximab reduces ischemic complications in patients
undergoing directional coronary atherectomy. EPILOG Investigators.
Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa
Receptor Blockade." American
Journal of Cardiology, 82 (1): 7-12, July 1, 1998.
Chung
MK, Schweikert RA, Wilkoff BL, Niebauer MJ, Pinski SL, Trohman RG, Kidwell
GA, Jaeger FJ, Morant VA, Miller DP, Tchou PJ. "Is hospital
admission for initiation of antiarrhythmic therapy with sotalol for atrial
arrhythmias required? Yield of in-hospital monitoring and prediction of
risk for significant arrhythmia complications.” Journal of the American College of Cardiology, 32(1):169-76,
July 1998.
Kleiman
NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM,
Weisman HF, Califf RM, Topol EJ. "Diabetes mellitus, glycoprotein
IIb/IIIa blockade, and heparin:
evidence for a complex interaction in a multicenter trial. EPILOG
Investigators." Circulation,
(19):1912-20, May 19, 1998.
Ellis
SG, Brown KJ, Ellert R, Howell GL, Miller DP, Flowers NM, Ott PA,
Keys T, Loop FD, Topol EJ. "Cost of cardiac care in the three years
after coronary catheterization in a contained care system: critical
determinants and implications."
Journal of the American
College of Cardiology,31(6):1306-13, May 1998.
Kereiakes
DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, Weisman
HF, Califf RM, Topol EJ. "Abciximab therapy and unplanned coronary
stent deployment: favorable effects on stent use, clinical outcomes, and
bleeding complications. EPILOG Trial Investigators." Circulation,97(9):857-64. March 10, 1998.
Brieger
DB, Mak KH, White HD, Kleiman NS, Miller DP, Vahanian A, Ross AM,
Califf RM, Topol EJ. "Benefit of early sustained reperfusion in
patients with prior myocardial infarction (the GUSTO-I trial). Global
Utilization of Streptokinase and TPA for occluded arteries." American Journal of Cardiology,
81(3):282-7, February 1, 1998.
Sgarbossa
EB, Pinski SL, Topol EJ, Califf RM, Barbagelata A, Goodman SG, Gates KB,
Granger CB, Miller DP, Underwood DA, Wagner GS. "Acute
myocardial infarction and complete bundle branch block at hospital
admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I
Investigators. Global Utilization of Streptokinase and t-PA [tissue-type
plasminogen activator] for Occluded Coronary Arteries."
Journal of the American College of Cardiology,
31(1):105-10, January 1998.
Topol
EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ,
Wang AL, Miller DP, Anderson KM, Califf RM, for the EPIC
Investigator Group. “Long-term Protection From Myocardial Ischemic Events
in a Randomized Trial of Brief Integrin Beta3 Blockade With
Percutaneous Coronary” JAMA, 278:479-484, August 13, 1997.
Mak
KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf
RM, Topol EJ. “Influence of
diabetes mellitus on clinical outcome in the thrombolytic era of acute
myocardial infarction. GUSTO-I Investigators. Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded Coronary
Arteries.” J Am Coll Cardiol, 30:1, 171-9, July
1997.
Simpfendorfer
C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove
CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ.
“First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade: A
Randomized, Placebo-Controlled Pilot Study of Xemilofiban in Unstable
Angina With Percutaneous Coronary Interventions” Circulation, 96:1, 76-81, July 1, 1997.
Migrino
RQ, Young JB, Ellis SG, White HD, Lundergran CF, Miller DP, Granger
CB, Ross AM, Califf RM, Topol EJ for the Global Utilization of
Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I
Angiographic Investigators. “End-Systolic Volume Index at 90 to 180 Minutes
Into Reperfusion Therapy for Acute Myocardial Infarction Is a Strong
Predictor of Early and Late Mortality” Circulation,
96:1, 116-121, July 1, 1997.
Moen
EK, Asher CR, Miller DP, Weaver WD, White HD, Califf RM, Topol EJ.
“Long-term follow-up of gender-specific outcomes after thrombolytic therapy
for acute myocardial infarction from the GUSTO-I trial. Global Utilization
of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary
Arteries.” J Womens Health, 6:3, 285-93, June
6, 1997.
Chung
MK, Pogwizd SM, Miller DP, Cain ME. “Three-dimensional mapping of the initiation of
nonsustained ventricular tachycardia in the human heart.” Circulation,
95:11, 2517-27, June 3, 1997.
The
EPILOG Investigators.
“Platelet glycoprotein IIb/IIIa receptor blockade and low-dose
heparin during percutaneous coronary revascularization..” New
England Journal of Medicine, 336:24, 1689-96, June 12, 1997.
Klein
AL, Grimm RA, Black IW, Leung DY, Chung MK, Vaughn SE, Murray RD, Miller
DP, Arheart KL, for the ACUTE Investigators. “Cardioversion Guided by Transesophaegeal
Echocardiography: The ACUTE
Pilot Study.” Annals of Internal Medicine. 126:200-209, February 1, 1997.
Wang
CW, Steinhubl SR, Castellani WJ, Van Lente F, Miller DP, James KB,
Young JB. “Inability of serum
myocyte death markers to predict acute cardiac allograft rejection.” Transplantation. 62:12, 1938-1941, December 27,
1996.
Pilote
L, Miller DP, Califf RM, Rao JS, Weaver WD, Topol EJ. “Determinants of the use of
coronary angiography and revascularization after thrombolysis for acute
myocardial infarction.” New England Journal of Medicine. 335:16, 1198-205, October 17, 1996.
Cohen GI, Duffy CI, Klein AL, Miller DP,
Cosgrove DM, Stewart WJ.
“Color Doppler and
two‑dimensional
echocardiolographic determination of the mechanism of aortic
regurgitation
with surgical correlation.” Journal of American Society of
Echocardiogram. 9:4, 508-515, Jul-Aug, 1996.
Fahy
GJ, Pinski SL, Miller DP, McCabe N, Pye C, Walsh MJ, Robinson
K. “Natural history of
isolated bundle branch block..”
American Journal of Cardiology. 77:14, 1185-1190, June 1, 1996.
Klein
AL, Murray RD, Black IW, Chandra S, Grimm RA, D’Sa AP, Leung DYC, Miller
DP, Morehead AJ Vaungh SE, Thomas JD. “Integrated Backscatter for
Quantification of Left Atrial Spontaneous Echo Contrast:” Journal
of the American College of Cardiology. 28:222-2231, July 1996.
Omoigui
NA, Miller DP, Brown KJ, Annan K, Cosgrove D, Loop F, Topol EJ.
“Potential explanation for decreased coronary bypass surgery related
mortality in New York State:
outmigration to Ohio.” Circulation, January 1, 1996.
Robinson
K, Mayer E, Miller DP, Green R, Gupta A, Kottke-Merchant K, Savon S,
Selhub J, Nissen S, Topol E, Kutner M, Jacobsen DW. “Hyperhomocysteinemia
and vitamin B6 deficiency:
common and independent reversible risk factors for coronary artery
disease.” Circulation, 92:2825-2830, November 15, 1995.
Cosgrove
DM, Lytle BW, Taylor PC, Camacho MT, Stewart RW, McCarthy PM, Miller DP,
Piedmonte MR, Loop FD. “The
Carpentier-Edwards pericardial aortic valve: Ten-year results.” Journal
of Thoracic and Cardiovascular Surgery. 110:651-662, September 1995.
Pilote
L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD, Gore JM,
Armstrong PW, Ohman EM, Topol EJ.
“Regional variation across the United States in the management of
acute myocardial infarction.” New England Journal of Medicine. 333:565-72, August 31, 1995.
Ellis
SG, Miller DP, Brown KJ, Omoigui N, Howell GL, Grierson J, Kutner M,
Topol EJ. “In-hospital cost of
percutaneous coronary revascularization: critical determinants and implications.” Circulation,
92:741-7, August 15, 1995.
Heric
B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. “Surgical management of
hypertrophic obstructive cardiomyopathy. Early and late results.” Journal
of Thoracic and Cardiovascular Surgery. 110:195-206, July 1995.
Steinbach
F, Novick A, Zincke H, Miller DP, Williams RD, Lund G, Skinner DG,
Esrig D, Richie JP, deKernion JB, Marshall F, Marsh CL. “Treatment of renal cell carcinoma
in von Hippel Lindau disease: a multicenter study.” The Journal of Urology, 153:1812-6, June 1995.
Butler
B, Novick A, Miller DP, Campbell SA, Licht MR. “Management of small unilateral
renal cell carcinomas: Radical versus nephron-sparing surgery.” The
Journal of Urology, 45:34-40, January 1995.
Manapat
AE, McCarthy PM, Lytle BW, Taylor PC, Loop FD, Stewart RW, Rosenkranz ER,
Sapp SK, Miller D, Cosgrove DM. “Gastroepiploic and inferior epigastric arteries for
coronary artery bypass: Early results and evolving applications.” Circulation,
90:II44-7, November 1994.
Steinbach
F, Stockle M, Griesinger A, Storkel S, Stein R, Miller DP,
Hohenfellner R. “Multifocal
renal cell tumors: A retrospective analysis of 56 patients treated with
radical nephrectomy.” The Journal of Urology, 152:1393-6,
November 1994.
Lepkowski
JM, Miller DP, Kalton G, Singh R. “Imputation for wave nonresponse in the SIPP.” Proceedings: Symposium '92, Design and analysis of longitudinal
surveys, Statistics Canada, 99-109, 1993.
Fix
J, Isada L, Cosgrove D, Miller DP, Savage R, Blum J, Stewart W. “Do patients with less than 'echo‑perfect'
results from mitral valve repair by intraoperative echocardiography have
different outcome?” Circulation, 88:II39-48, November
1993.
Miller
DP, Kalton G, Lepkowski J. “Estimating Duration of Food Stamp
Spells from the SIPP.” ASA Proceedings of Survey Research
Methods Section. 560-565, 1992.
Kelsey
SF, Miller DP, Holoblov R, Lu AS, Cowley MJ, Faxon DP, Detre KM, and
investigators from the NHLBI PTCA registry. “Results of Percutaneous Transluminal Coronary
Angioplasty in Patients >65 Years of Age (from the 1985 to 1986 National
Heart, Lung, and Blood Institute's Coronary Angioplasty Registry).” American
Journal of Cardiology. 1033-1038, November 1, 1990.
|
|
